Merck KGaA Future Growth

Future criteria checks 1/6

Merck KGaA is forecast to grow earnings and revenue by 10.7% and 4.1% per annum respectively. EPS is expected to grow by 11% per annum. Return on equity is forecast to be 12.9% in 3 years.

Key information

10.7%

Earnings growth rate

11.0%

EPS growth rate

Pharmaceuticals earnings growth	15.8%
Revenue growth rate	4.1%
Future return on equity	12.9%
Analyst coverage	Good
Last updated	22 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BUL:MRK - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	23,024	3,696	3,733	5,255	13
12/31/2025	22,057	3,390	3,304	5,006	14
12/31/2024	21,150	2,933	3,011	4,597	14
9/30/2024	20,963	2,696	2,160	4,408	N/A
6/30/2024	20,870	2,626	2,052	4,205	N/A
3/31/2024	20,820	2,722	1,961	3,966	N/A
12/31/2023	20,993	2,824	1,897	3,784	N/A
9/30/2023	21,428	2,893	1,912	3,746	N/A
6/30/2023	22,061	3,078	2,198	4,042	N/A
3/31/2023	22,327	3,242	2,334	4,272	N/A
12/31/2022	22,232	3,326	2,491	4,259	N/A
9/30/2022	21,785	3,473	2,788	4,289	N/A
6/30/2022	20,952	3,311	2,658	4,204	N/A
3/31/2022	20,254	3,188	2,734	4,240	N/A
12/31/2021	19,687	3,055	3,234	4,616	N/A
9/30/2021	19,072	2,689	3,125	4,859	N/A
6/30/2021	18,546	2,733	3,073	4,562	N/A
3/31/2021	17,795	2,278	2,702	4,177	N/A
12/31/2020	17,534	1,987	2,002	3,477	N/A
9/30/2020	17,317	1,884	1,684	2,879	N/A
6/30/2020	16,924	1,419	1,498	2,640	N/A
3/31/2020	16,776	1,549	1,729	2,879	N/A
12/31/2019	16,152	1,292	1,858	2,856	N/A
9/30/2019	15,658	1,139	1,967	2,906	N/A
6/30/2019	15,354	1,118	1,751	2,706	N/A
3/31/2019	15,096	938	1,425	2,332	N/A
12/31/2018	14,836	1,071	1,270	2,219	N/A
9/30/2018	14,597	1,921	1,031	2,120	N/A
6/30/2018	14,364	2,218	N/A	2,147	N/A
3/31/2018	14,346	2,389	N/A	2,299	N/A
12/31/2017	14,517	2,548	N/A	2,696	N/A
9/30/2017	14,699	1,787	N/A	2,842	N/A
6/30/2017	14,906	1,628	N/A	3,152	N/A
3/31/2017	15,016	1,529	N/A	2,943	N/A
12/31/2016	15,024	1,629	N/A	2,518	N/A
9/30/2016	14,658	1,480	N/A	2,449	N/A
6/30/2016	14,054	1,387	N/A	2,253	N/A
3/31/2016	13,469	1,418	N/A	2,268	N/A
12/31/2015	12,845	1,109	N/A	2,195	N/A
9/30/2015	12,380	1,269	N/A	2,618	N/A
6/30/2015	12,180	1,154	N/A	2,472	N/A
3/31/2015	11,776	1,114	N/A	2,576	N/A
12/31/2014	11,363	1,157	N/A	2,706	N/A
9/30/2014	11,106	1,158	N/A	2,005	N/A
6/30/2014	10,937	1,249	N/A	2,105	N/A
3/31/2014	10,963	1,261	N/A	2,119	N/A
12/31/2013	11,095	1,202	N/A	2,226	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRK's forecast earnings growth (10.7% per year) is above the savings rate (3%).

Earnings vs Market: MRK's earnings (10.7% per year) are forecast to grow slower than the BG market (13.8% per year).

High Growth Earnings: MRK's earnings are forecast to grow, but not significantly.

Revenue vs Market: MRK's revenue (4.1% per year) is forecast to grow slower than the BG market (24.6% per year).

High Growth Revenue: MRK's revenue (4.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MRK's Return on Equity is forecast to be low in 3 years time (12.9%).

Merck KGaA Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Recent updates

Merck KGaA to Report Q4, 2024 Results on Mar 06, 2025

Third quarter 2024 earnings released: EPS: €1.86 (vs €1.70 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Merck KGaA Announces Phase III Maneuver Trial of Pimicotinib

Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million.

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

Merck KGaA, Annual General Meeting, Apr 25, 2025

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Merck KGaA, Annual General Meeting, Apr 26, 2024

Merck Announces CFO Changes

Upcoming dividend of €2.20 per share at 1.4% yield

Upcoming dividend of €2.20 per share at 1.3% yield

Full year 2022 earnings released

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

Second quarter 2022 earnings released: EPS: €1.99 (vs €1.71 in 2Q 2021)

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies